Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 10/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848633 | 0.88 | DRD2 (0.38) | DRD2DRD4DRD3ALOX15CREBBP | |
| SCHEMBL5847633 | 0.72 | DRD3 (0.41) | DRD2DRD4DRD3CRHR1SLC6A2 | |
| SCHEMBL5847485 | 0.72 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL5848414 | 0.72 | CRHR1 (0.41) | CRHR1SLC6A2ALOX15CREBBP | |
| SCHEMBL5848619 | 0.71 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL25045802 | 0.70 | DRD2 (0.40) | DRD2DRD4DRD3 | |
| SCHEMBL25044269 | 0.69 | DRD2 (0.41) | DRD2DRD4DRD3 | |
| SCHEMBL5849088 | 0.65 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL27274738 | 0.62 | CRHR1 (0.39) | CRHR1SLC6A2ALOX15CREBBP | |
| SCHEMBL25276682 | 0.62 | CRHR1 (0.36) | DRD3CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151109-B2 | Pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-12-19 | — | — | US | disclosed |
| US-20040002511-A1 | Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | PHARMACIA & UPJOHN COMPANY | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002511-A1 | Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | CRHR1, HTR5A, CRH | DRD2 145/4885DRD4 184/4885DRD3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.